Renal Manifestations in Juvenile Idiopathic Arthritis (JIA) And The Use Of Monoclonal Antibodies For Its Treatment: A Systematic Review


  • Umaima Fatima
  • Aaiyat Sheikh
  • Chaitanya S. Puvvada
  • Faiza H. Soomro
  • Hafsa A. Osman Merna Haridi
  • Natalie A. Gonzalez
  • Sana M. Dayo
  • Ann Kashmer Yu



Juvenile idiopathic arthritis, Renal manifestations, Nephropathy, Nephropathy Nephropathy, Tocilizumab


Juvenile idiopathic arthritis (JIA) is a group of chronic
childhood arthropathies in which various joints are
affected. Along with the joints being involved, long-standing arthritis can lead to other systemic
involvements. Eyes, kidneys, and skin are some
examples. It is no surprise that we come across many
patients suffering from renal complications due to long-standing JIA. This systematic review aimed to focus on
the renal involvement seen in JIA and the use of
monoclonal antibodies in its treatment. A systematic
review was performed using the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and researching studies on
databases like PubMed, PubMed Central, and Google
Scholar on June 26, 2022. Assessment tools like
Cochrane, SANRA, and JBI Tool were used for quality
assessment and the selection of articles. Followed by
the quality assessment, seven studies were included in
the final selection. These were two randomized control
trials, four case reports, and one literature review. In
conclusion, many cases involving renal complications
along with JIA were seen, and Tocilizumab has proved
to be efficacious in improving renal complications in
JIA. This review encourages further study and research
into the topic to understand the effects on JIA and the
use of monoclonal antibodies as therapy